ep. 13: avoiding repeat lines of ar-targeted therapy in mcrpc
Published 4 years ago • 48 plays • Length 7:07Download video MP4
Download video MP3
Similar videos
-
8:30
ar-targeted therapies in crpc
-
9:00
differences between ar-targeted therapy in prostate cancer
-
8:21
ep. 10: how has the mcrpc treatment landscape changed?
-
7:12
ep. 8: selecting optimal ar-targeted therapy for nmcrpc
-
3:55
optimal treatment approaches for mcrpc
-
1:02
dr. oh on choosing ar-targeted therapy versus chemotherapy in mhspc
-
3:33
prophecy trial: ar-v7 ctcs as a biomarker in mcrpc
-
3:51
impressions of a patient with progression to mcrpc
-
10:33
ep. 12: what is radium 223’s role in mcrpc management?
-
1:41
dr. antonarakis on ar-v7 and resistance to ar-targeting agents in mcrpc
-
20:48
point-counterpoint: management of mcrpc
-
4:50
card trial: cabazitaxel after ar-targeted therapy in mcspc
-
7:52
case 3: treatment after progression to mcrpc
-
11:00
treatment approaches for newly diagnosed mcrpc
-
14:14
management of mcrpc in china
-
39:02
systemic therapies for the treatment of advanced prostate cancer
-
10:55
emerging therapies for advanced prostate cancer
-
2:03
dr. grivas on the role of targeted therapy in prostate cancer
-
3:56
bone-targeted therapy for prostate cancer: radium-223